Innovations In Clinical Neuroscience

Pain Management August 2016

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: http://innovationscns.epubxp.com/i/716904

Contents of this Issue

Navigation

Page 16 of 35

Hot Topics in Pain Management [August 2016] 17 comparison of acute and chronic signaling to adenylyl cyclase. J Biol Chem. 2009;284:22108–22. 20. Alfaro MJ, Ormazabal MJ, Garcia- Arroba L, Martin MI. Cholesterol- fed rabbits: study of the response of the vas deferens to adrenergic and non-adrenergic stimulus and to a kappa-opioid agonist. J Pharm Pharmacol. 1996;48:433–6. 21. Hong QY, Wu GM, Qian GS, Hu CP, Zhou JY, Chen LA, et al. Prevention and management of lung cancer in China. Cancer. 2015;121 Suppl 17:3080–8. 22. Shi Y, Sun Y. Medical management of lung cancer: experience in China. Thorac Cancer. 2015;6:10–6. 23. Yang W, Xiao J, Yang Z, Ji L, Jia W, Weng J, et al. Serum lipids and lipoproteins in Chinese men and women. Circulation. 2012;125:2212–21. 24. Zheng H, Chu J, Zhang Y, Loh HH, Law PY. Modulating micro-opioid receptor phosphorylation switches agonist-dependent signaling as reflected in PKCepsilon activation and dendritic spine stability. J Biol Chem. 2011;286:12724–33. 25. Duttaroy A, Yoburn BC. The effect of intrinsic efficacy on opioid tolerance. Anesthesiology. 1995;82:1226–36. 26. Foley KM. The treatment of cancer pain. N Engl J Med. 1985;313:84– 95. 27. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain. 1996;64:527–34. 28. McNicol E. Opioid side effects and their treatment in patients with chronic cancer and noncancer pain. J Pain Palliat Care Pharmacother. 2008;22:270–81. 29. Whittaker MR. Opioid use and the risk of respiratory depression and death in the pediatric population. J Pediatr Pharmacol Ther. 2013;18:269–76. 30. Juni A, Klein G, Pintar JE, Kest B. Nociception increases during opioid infusion in opioid receptor triple knock-out mice. Neuroscience. 2007;147:439–44. 31. Garcia-Sevilla JA, Ferrer-Alcon M, Martin M, Kieffer BL, Maldonado R. Neurofilament proteins and cAMP pathway in brains of mu-, delta- or kappa-opioid receptor gene knock- out mice: effects of chronic morphine administration. Neuropharmacology. 2004;46:519– 30. 32. Dietschy JM, Turley SD. Control of cholesterol turnover in the mouse. J Biol Chem. 2002;277:3801–4. 33. Barnett-Norris J, Lynch D, Reggio PH. Lipids, lipid rafts and caveolae: their importance for GPCR signaling and their centrality to the endocannabinoid system. Life Sci. 2005;77:1625–39. 34. Bliss SP, Navratil AM, Breed M, Skinner DC, Clay CM, Roberson MS. Signaling complexes associated with the type I gonadotropin-releasing hormone (GnRH) receptor: colocalization of extracellularly regulated kinase 2 and GnRH receptor within membrane rafts. Mol Endocrinol. 2007;21:538–49. 35. Navratil AM, Bliss SP, Berghorn KA, Haughian JM, Farmerie TA, Graham JK, et al. Constitutive localization of the gonadotropin- releasing hormone (GnRH) receptor to low density membrane microdomains is necessary for GnRH signaling to ERK. J Biol Chem. 2003;278:31593–602. 36. Morris DP, Lei B, Wu YX, Michelotti GA, Schwinn DA. The alpha1a-adrenergic receptor occupies membrane rafts with its G protein effectors but internalizes via clathrin-coated pits. J Biol Chem. 2008;283:2973–85. 37. Bari M, Battista N, Fezza F, Finazzi-Agro A, Maccarrone M. Lipid rafts control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for anandamide-induced apoptosis. J Biol Chem. 2005;280:12212–20. 38. Eglen RM, Reisine T. New insights into GPCR function: implications for HTS. Methods Mol Biol. 2009;552:1–13. 39. Eglen RM. Functional G protein- coupled receptor assays for primary and secondary screening. Comb Chem High Throughput Screen. 2005;8:311–8. 40. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829–39. 41. Robson J. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Heart. 2008;94:1331–2. 42. Duane WC, Hunninghake DB, Freeman ML, Pooler PA, Schlasner LA, Gebhard RL. Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile. Hepatology. 1988;8:1147–50. 43. Abeatici S, Castagno PL, Palestini N, Nieddu L. [Blood cholesterol in patients with cancer]. Minerva Med. 1989;80:1085–90. 44. Simo Camps E, Orti Llaveria A, Sena Ferrer F, Contreras Barbeta E. [Blood cholesterol in patients with cancer]. An Med Interna. 1998;15:363–6. 45. Fiorenza AM, Branchi A, Cardena A, Molgora M, Rovellini A, Sommariva D. Serum cholesterol levels in patients with cancer. Relationship with nutritional status. Int J Clin Lab Res. 1996;26:37–42. 46. Ware LJ, Epps CD, Herr K, Packard A. Evaluation of the revised faces pain scale, verbal descriptor scale, numeric rating scale, and Iowa pain thermometer in older minority adults. Pain Manag Nurs. 2006;7:117–25.

Articles in this issue

Archives of this issue

view archives of Innovations In Clinical Neuroscience - Pain Management August 2016